Please assess the completion status of the following clinical trial:

Trial Title: Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Inform Consent~* Age \> 70 years.~* Histologically documented metastatic colorectal cancer not candidate for surgical resection~* Wild type K-RAS~* Measurable disease by RECIST Criteria~* Intermediate or High-risk group according to the Köhne Prognostic Classification~* ECOG status \< 3~* Magnesium ≥ institutional lower limit of normal~* frail elderly patients and or not candidates for chemotherapy:~Frail elderly patients: Presence of one or more of the following criteria:~* Dependence for one of the basic daily living activities (Katz Index)~* Three or more comorbid conditions according Charlson scale and dependence for one of the instrumental activities of daily living (IADL)~* Presence one or more of the following geriatric syndromes (age \> 85 years, fecal or urinary incontinence in the absence of stress, frequent falls, spontaneous bone fractures, neglect)~Presence of one or more of the following criteria that make patients not candidates for chemotherapy:~* neutrophils \< 2000/mm3~* platelets \< 100.000/mm3~* creatinine clearance \< 30 ml/min and bilirubin levels \> 1.5 x ULN~* creatinine clearance \< 30 ml/min and AST or ALT levels \> 3 x UNL (if liver metastasis \> 5 x ULN)~Exclusion Criteria:~* Patients will be excluded from the study if they have received prior systemic therapy for the treatment of metastatic colorectal carcinoma or antiEGFR therapy, with the exception of adjuvant fluoropyrimidine-based chemotherapy given at least six months prior to enrolment or oxaliplatin at least 12 months prior to enrolment.~* Systemic chemotherapy, hormonal therapy, immunotherapy or experimental or approved proteins/antibodies (eg, bevacizumab) ≤ 30 days before inclusion~* Unresolved toxicities from prior systemic therapy that, in the opinion of the investigator, does not qualify the patient for inclusion~* Patients cognitively impaired or with severe depression according mini mental state examination and geriatric depression scale.~* Patients with central nervous system metastases, or those with significant cardiovascular disease, will also be excluded.~* History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest CT scan~* Treatment for systemic infection within 14 days before initiating study treatment~* Radiotherapy \< 14 days prior to inclusion in the study.~* Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea (defined as \> 4 loose stools per day)~* History of any medical condition that may increase the risks associated with study participation or may interfere with the interpretation of the study results~* Known positive test for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection~* subject allergic to the ingredients of the study medication or to Staphylococcus protein A~* Any co-morbid disease that would increase risk of toxicity~* Any investigational agent within 30 days before enrolment~* Must not have had a major surgical procedure within 28 days of enrolment~* Subject unwilling or unable to comply with study requirements

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panitumumab (Type: EXPERIMENTAL): Panitumumab: 6 mg/Kg Q2W Treatment cycles repeated every 14 days. Subjects will be evaluated for tumour response every 3 cycles (6 wks ± 1 wk) the first 24 weeks and every 8 weeks ± 2 weeks thereafter (per the revised-RECIST 1.1 guideline) until PD or withdrawal from the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).